Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

iShares Biotechnology ETF (NQ:IBB)

170.12 +1.19 (+0.70%)
Streaming Delayed Price Updated: 10:09 AM EST, Dec 11, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about iShares Biotechnology ETF

< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
27 28 Next >
News headline image
Look Who’s Leading Now ↗
All indexes are near either their 50 or 200 DMA’s as we head into the Fed’s announcement tomorrow. 
Via Talk Markets
News headline image
Provention Bio's Second Try, Apellis's Eye Disorder Drug Review, 3 Adcom Verdicts And More: November's Key PDUFA Catalysts Biotech Investors Must Know ↗
October proved to be a mixed month for the Food and Drug Administration’s regulatory decisions. Two new molecular entities, or NMEs, were approved during the month, bringing the tally for the... 
Via Benzinga
News headline image
Can Biotech Stocks Continue Rallying In This Bear Market? ↗
Via Talk Markets
News headline image
October Was Not So Scary After All - Things To Keep A Watch Out For ↗
Via Talk Markets
News headline image
These 4 ETFs Feature on CNBC's 'Final Trades' ↗
On CNBC’s “Halftime Report Final Trades,” JPMorgan Private Bank’s Anastasia Amoroso chose iShares iBoxx $ High Yield Corporate Bond ETF (NYSE: HYG), saying that she wanted &ldq 
Via Benzinga
News headline image
Russell 2000: How Money Is Made And Lost In Small Caps ↗
IWM is in a bearish phase along with the other indices, but recent price action has shown relative strength. 
Via Talk Markets
News headline image
The Four Indices: Where Each Are In A 4-Year Cycle ↗
In the aftermath of last week’s market plunge and continued rally since, it is worth noting that the 200-week historic weekly support levels held for the SPY and the DIA, both of which were in danger... 
Via Talk Markets
News headline image
Steady As She Goes With Healthcare Stocks ↗
Favorable seasonality lies ahead for Q4 with a caveat of Q3 earnings reports. 
Via Talk Markets
News headline image
Precarious Action In The Bonds And Stock Market ↗
Analysts and researchers claimed that double thrusts in the market have always preceded positive returns. Always, huh? 
Via Talk Markets
News headline image
Taking The Temperature Of The Major Sector ETFs ↗
One of the most important first steps towards trading success is to tilt your trading towards trending sectors that display strength and avoid market weakness. 
Via Talk Markets
News headline image
3 Technical Lessons On Whether Or Not Semiconductors Bottomed ↗
The semis ETF SMH has three interesting technical features that are a reliable way to assess what to do from here and how to know if this rally will last. 
Via Talk Markets
News headline image
AstraZeneca-Merck's Prostate Cancer Combo Drug, 3rd Try For scPharma, 3 FDA Panel Decisions And More: October's Key PDUFA Catalysts Biotech Investors Must Know ↗
Most FDA decisions scheduled for September yielded positive results, but there were stray disappointments as well. Seven new molecular entities, or NMEs, were approved during the month, taking the... 
Via Benzinga
News headline image
The 7 Best Stocks to Buy to Tap Into a Hidden Bull Market ↗
Despite the ongoing worries on Wall Street, these are the best stocks to buy to play the hidden bull market. 
Via InvestorPlace
News headline image
Step Back To The Monthly Chart On Transportation ↗
The chart of IYT is a perfect example of the monthly moving average and what to watch for. 
Via Talk Markets
News headline image
Can Healthcare Stocks Continue To Outperform? ↗
Large-cap healthcare and biotech stocks have been resilient amidst the market turmoil caused by rising rates and the global geopolitical crisis. 
Via Talk Markets
News headline image
The Biotech Sector Should Come Back First ↗
We are looking for profitable opportunities to deploy dry powder. Many areas of biotech show incredible promise, including regenerative medicine, gene therapy, genomics, new advances in treating cancer... 
Via Talk Markets
News headline image
The Major Sector ETFs Reveal All For Investors ↗
Semiconductors have been a significant drag on Wall Street. 
Via Talk Markets
News headline image
Healthcare Sector Still Looks Good But Lacks Momentum ↗
The summer rally is over it’s a holiday weekend with low trading volume and bad news is pervasive. A decent jobs report on Friday brought in buyers in early hours until Russia intervened with a Nord... 
Via Talk Markets
News headline image
Bluebird bio Seeks Back-to-Back Nods, 'Go' or 'No-Go' For Revance's Botox Rival, Amylyx' Twin Hurdles And More: September's Key PDUFA Catalysts Biotech Investors Must Know ↗
After August’s mixed tally for Food and Drug Administration approvals, investors turn to a new month, which has a fairly loaded calendar. 
Via Benzinga
News headline image
Potential Signs That Could Derail The Economy ↗
The last six weeks have brought a partial market recovery. Most of the media and financial reporters have been telling us how much better everything now seems. 
Via Talk Markets
News headline image
Biotech Daily: Cancer Causing Impurities In Merck's Diabetic Drug, Vir Bio-GSK Shun FDA Submission Plans For COVID-19 Treatment, Aethlon's Monkeypox Trial ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Biotech Daily: Regulatory Setback For CorMedix, Mersana & GSK In Cancer Pact, BARDA Funding For Opioid Overdose Hopeful ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Biotech Daily: Thumbs Down For Acadia's Antipsychotic Drug, Akebia Fails COVID-19 Study, Kazia's Encouraging Data In Brain Metastases ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Biotech Daily: Amgen, Gilead Go Shopping, Nod For AstraZeneca's Lynparza In Early Stage Breast Cancer, Decision Day For Alzheimer's Associated Hallucinations Candidate ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Biotech Daily: Merck's Two Combo Cancer Trials Miss Main Goal, Approval For Sinovac's COVID-19 Shot For Youngest Kids, Alnylam Aces Protein Disorder Trial ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Biotech Daily: Trial Setback For Eliem Therapeutics, Allarity Drops Work On Cancer Monotherapies, Axcella Aces Long COVID Study ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Daily Biotech Pulse: Celyad Resumes Colorectal Cancer Trial, Setback For Otonomy, AstraZeneca Halts Phase 3 Head, Neck Cancer Trial ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Biotech Investors: August's Key PDUFA Catalysts You Must Know ↗
Regulatory decisions have yet to pick up pace this year. July’s calendar was light, but the good news was that most decisions turned out to be positive. That said, none of the drugs approved during the... 
Via Benzinga
News headline image
Daily Biotech Pulse: Bausch Health To Appeal Xifaxan Patent Decision, Bristol Myers Drug Combo Fails In Kidney Cancer Trial, Sarepta's Duchenne Candidate Update ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Daily Biotech Pulse: GSK's Kidney Disease Drug Approved For Children, Tonix Pharma To Launch Monkeypox Vaccine Study In Kenya, Positive Effect Of Cyclerion's Schizophrenia Candidate ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
27 28 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.